Relapsed Pediatric ALL
Publisher
Springer Singapore
Reference79 articles.
1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166–78.
2. Tsuchida M, Ohara A, Manabe A, Kumagai M, Shimada H, Kikuchi A, et al. Long-term results of Tokyo Children's cancer study group trials for childhood acute lymphoblastic leukemia, 1984–1999. Leukemia. 2010;24(2):383.
3. Schrappe M, Bleckmann K, Zimmermann M, Biondi A, Möricke A, Locatelli F, et al. Reduced-intensity delayed intensification in standard-risk pediatric acute lymphoblastic leukemia defined by undetectable minimal residual disease: results of an international randomized trial (AIEOP-BFM ALL 2000). J Clin Oncol. 2018;36(3):244–53.
4. Tallen G, Ratei R, Mann G, Kaspers G, Niggli F, Karachunsky A, et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol. 2010;28(14):2339–47.
5. Gaynon PS, Harris RE, Altman AJ, Bostrom BC, Breneman JC, Hawks R, et al. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: children's oncology group study CCG-1941. J Clin Oncol. 2006;24(19):3150–6.